好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Phase II Clinical Trial (Halt MS: Immune Tolerance Network) of High Dose Immunosuppressive Therapy (HDIT) and Autologous Hematopoetic Stem Cell Transplantation (AHSCT) for Active Relapsing-Remitting (RR) Multiple Sclerosis (MS): Early Results
MS and Related Diseases
(-)
179
Authors/Disclosures
George H. Kraft, MD (University of Washington) No disclosure on file
Brigid Dwyer, MD Dr. Dwyer has nothing to disclose.
James D. Bowen, MD (Swedish Neuroscience Institute) Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen IDEC. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BristolMyers Squibb. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Bowen has received research support from Biogen IDEC. The institution of Dr. Bowen has received research support from Genentech. The institution of Dr. Bowen has received research support from Genzyme. The institution of Dr. Bowen has received research support from Novartis. The institution of Dr. Bowen has received research support from Roche.
Harry O. Openshaw, MD No disclosure on file
No disclosure on file
Elliot M. Frohman, MD, FAAN Dr. Frohman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Frohman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Janssen. Dr. Frohman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Up To Date. Dr. Frohman has received publishing royalties from a publication relating to health care.
No disclosure on file
George J. Hutton, MD, FAAN (Baylor College of Medicine) Dr. Hutton has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Autoimmunity Biologic Solutions, Inc.. The institution of Dr. Hutton has received research support from Biogen. The institution of Dr. Hutton has received research support from Genentech. The institution of Dr. Hutton has received research support from Genzyme.
Paolo A. Muraro, MD, PhD (Neuroimmunolofy/Branch/NINDS/NIH) No disclosure on file
No disclosure on file
Michael K. Racke, MD (Quest Diagnostics) Dr. Racke has received personal compensation for serving as an employee of Quest Diagnostics. Dr. Racke has or had stock in Quest Diagnostics.Dr. Racke has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Olaf Stuve, MD, PhD, FAAN (UT Southwestern Medical Center) Dr. Stuve has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurological Diseases. Dr. Stuve has received research support from US Department of Veterans Affairs. Dr. Stuve has received research support from National Multiple Sclerosis Society (US). Dr. Stuve has received research support from Merck KGaA.
Annette Wundes, MD, FAAN (University of Washington) The institution of Dr. Wundes has received research support from Benaroya Research Institute .
No disclosure on file
Sarah Wahlster, MD Dr. Wahlster has nothing to disclose.